EN · OpenOnco · DIS-MELANOMA — Auto-stub (88% наповненість)
← Back to galleryFeedback on this caseUA
OpenOnco · Treatment Plan
Treatment plan — DIS-MELANOMA
PLAN-AUTO-MELANOMA-001-V1 · v1 · 2026-04-27
Patient
AUTO-MELANOMA-001 · Algorithm: ALGO-MELANOMA-METASTATIC-1L

Clinical significance of mutations (ESCAT / OncoKB)

Tumor-board context — the engine does not use these tiers to rank tracks
BiomarkerVariantESCATOncoKBClinical significanceDrugsSources
No clinically actionable variants matched in this profile.

Treatment options (2 tracks)

Standard plan
★ DEFAULT
Indication
IND-MELANOMA-METASTATIC-1L-NIVO-IPI
Regimen
Nivolumab + ipilimumab (melanoma, 1L metastatic)
Drugs + NSZU
  • Nivolumab (DRUG-NIVOLUMAB) 1 mg/kg IV induction → 480 mg flat IV q4w maintenance · Induction with ipi cycles 1-4 · IV ✓ NSZU covered
  • Ipilimumab (DRUG-IPILIMUMAB) 3 mg/kg IV (higher than RCC) · Days 1 of cycles 1-4 · IV ✓ NSZU covered
Reason
Engine default per algorithm ALGO-MELANOMA-METASTATIC-1L: {'step': 1, 'outcome': False, 'branch': {'result': 'IND-MELANOMA-METASTATIC-1L-NIVO-IPI'}, 'fired_red_flags': [], 'winner_red_flag': None}
Aggressive plan
Indication
IND-MELANOMA-BRAF-METASTATIC-1L-DABRA-TRAME
Regimen
Dabrafenib + trametinib (BRAF V600E+ NSCLC)
Drugs + NSZU
  • Dabrafenib (DRUG-DABRAFENIB) 150 mg PO BID · Continuous · PO ✓ NSZU covered
  • Trametinib (DRUG-TRAMETINIB) 2 mg PO once daily · Continuous · PO ✓ NSZU covered
Reason
Alternative track presented for HCP consideration

Pre-treatment investigations

Investigations before treatment start · critical / standard / desired · merged across tracks
IDNamePriorityCategoryNeeded for
TEST-CECT-CAPКТ органів грудної клітки/черевної порожнини/таза з внутрішньовенним контрастуваннямCriticalimagingall tracks
TEST-BRAIN-MRI-CONTRASTМРТ головного мозку з контрастомStandard—all tracks

Red flags — PRO / CONTRA aggressive

PRO-AGGRESSIVE

Triggers that push toward the aggressive track
  • Symptomatic CNS metastases — ICI doublet (nivo+ipi) intracranially active; BRAFi+MEKi for visceral crisis.RF-MELANOMA-TRANSFORMATION-PROGRESSION

CONTRA-AGGRESSIVE

Hard contraindications to escalation
  • —

Timeline

Treatment timeline — derived from regimen + monitoring schedule

Standard plan

Induction · Nivolumab + ipilimumab (melano
21-day cycles × 4 induction; nivo maintenance until progression OR 2 years

Aggressive plan

Induction · Dabrafenib + trametinib (BRAF
28-day cycles × Continuous until progression

MDT brief

Skills (recommended) — for consideration (2)

  • Клінічний фармацевт recommended
    Хіміоімунотерапевтичний схема — drug-drug interactions, dose adjustments, premedication.
    skill: clinical_pharmacistv0.1.0reviewed 2026-04-25STUBsign-offs: 0lead: TBD
  • Молекулярний генетик / молекулярний онколог recommended
    Indication посилається на actionable геномний біомаркер — потрібна інтерпретація мутації / target / actionability.
    skill: molecular_geneticistv0.1.0reviewed 2026-04-25STUBsign-offs: 0lead: TBD

Open questions (1, 0 blocking)

  • OQ-LDH-CURRENT
    Який актуальний LDH? Маркер пухлинного навантаження і трансформації.
    LDH входить у прогностичні індекси індолентних лімфом.
    → hematologist

Data quality

  • Unevaluated RedFlags: RF-MELANOMA-BRAF-V600-ACTIONABLE, RF-MELANOMA-FRAILTY-AGE, RF-MELANOMA-HIGH-RISK-BIOLOGY, RF-MELANOMA-INFECTION-SCREENING, RF-MELANOMA-IO-RESISTANT, RF-MELANOMA-KIT-MUT-ACTIONABLE, RF-MELANOMA-ORGAN-DYSFUNCTION, RF-MELANOMA-TRANSFORMATION-PROGRESSION

Skill catalog (2/16 activated in this plan)

All registered virtual specialists. ✓ — activated for this case; ○ — not activated (available for other clinical scenarios).
Specialistskill_idVersionLast reviewedSign-offsDomain
Specialist з клітинної терапії (CAR-T)cellular_therapy_specialistv0.1.02026-04-250cellular_therapy
Клінічний фармацевтclinical_pharmacistv0.1.02026-04-250clinical_pharmacy
Гематолог / онкогематологhematologistv0.1.02026-04-250hematology_oncology
Гематопатолог (специфічно для лімфом / лейкозів / мієломи)hematopathologistv0.1.02026-04-250hematopathology
Інфекціоніст / гепатологinfectious_disease_hepatologyv0.1.02026-04-250infectious_diseases
Медичний онколог (хіміотерапевт солідних пухлин)medical_oncologistv0.1.02026-04-250solid_oncology
Молекулярний генетик / молекулярний онкологmolecular_geneticistv0.1.02026-04-250molecular_oncology
Паліативна допомогаpalliative_carev0.1.02026-04-250palliative_care
Патолог (загальний)pathologistv0.1.02026-04-250pathology
Сімейний лікар / терапевтprimary_carev0.1.02026-04-250primary_care
Психолог / онкопсихологpsychologistv0.1.02026-04-250psychosocial
Радіотерапевт (променева терапія)radiation_oncologistv0.1.02026-04-250radiation_oncology
Лікар-радіологradiologistv0.1.02026-04-250diagnostic_imaging
Соціальний працівник / кейс-менеджерsocial_worker_case_managerv0.1.02026-04-250psychosocial
Хірург-онкологsurgical_oncologistv0.1.02026-04-250surgical_oncology
Specialist з трансплантації (BMT)transplant_specialistv0.1.02026-04-250cellular_therapy

Sources cited

Експериментальні опції (клінічні дослідження)

Третій трек плану — open-enrollment trials з ClinicalTrials.gov. Останнє оновлення: 2026-04-27. Render-time metadata; engine selection не змінюється цим блоком (CHARTER §8.3).
NCTNamePhaseСтатусСпонсорUAВключення (фрагмент)
NCT06466434Prebiotic Food-enriched Diet (PreFED) to Enhance the Microbiome and Response to First-line Immunotherapy in Unresectable MelanomaPHASE2RECRUITINGM.D. Anderson Cancer Center—
NCT06428721The Preventive Role of Fractionated Laser Resurfacing Against Actinic Neoplasia in an At-Risk Geriatric PopulationNARECRUITINGWright State University—
NCT04318717Pembrolizumab and Hypofractionated Radiation Therapy for the Treatment of Mucosal MelanomaPHASE2RECRUITINGWashington University School of Medicine—
NCT06889766NY-ESO-1-redirected T Cells in Patients With Advanced Melanoma and SarcomaPHASE1RECRUITINGCentre Hospitalier Universitaire Vaudois—
NCT04291105Phase 2 Trial of Voyager V1 in Combination With Cemiplimab in Cancer PatientsPHASE2RECRUITINGVyriad, Inc.—
NCT07230613Neo-adjuvant Immunotherapy in Patients With Localized MelanomaPHASE2RECRUITINGUNICANCER—
NCT07379138Studying Quality of Life Inclusive of Mental Health and Cognitive Behavioral Therapy for Cancer Distress for the Improvement of Quality of Life in Stage III-IV Melanoma PatientsNARECRUITINGMayo Clinic—
NCT06028724A Study on the Prevalence of Clinically Useful Mutations in Solid Tumor Characterized by Next Generation Sequencing Methods on Liquid Biopsy Analysis (POPCORN)N/ARECRUITINGCentro di Riferimento Oncologico - Aviano—
NCT06797297A Study to Evaluate the Efficacy and Safety of IBI363 Monotherapy Compared to Pembrolizumab in Patients With Unresectable Locally Advanced or Metastatic Mucosal or Acral Melanoma Who Had Not Previously Received Systemic TherapyPHASE2RECRUITINGInnovent Biologics (Suzhou) Co. Ltd.—
NCT03740503Genomic Investigation of Unusual RespondersN/ARECRUITINGUniversity Health Network, Toronto—

Перевіряти статус набору безпосередньо у дослідницькому центрі. Дані ctgov можуть відставати від поточного статусу UA-сайтів.

Доступність опцій в Україні

Per-track UA registration · НСЗУ · cost · access pathway. Render-time metadata; engine selection не залежить від цих полів (CHARTER §8.3).
ОпціяРеєстрація UAНСЗУCost orientationAccess pathway
Standard plan
Nivolumab + ipilimumab (melanoma, 1L metastatic) (REG-NIVO-IPI-MELANOMA)
✓ зареєстровано✓ покривається₴-? — verify pathwayНСЗУ formulary
Aggressive plan
Dabrafenib + trametinib (BRAF V600E+ NSCLC) (REG-DABRAFENIB-TRAMETINIB-NSCLC)
✓ зареєстровано✓ покривається₴-? — verify pathwayНСЗУ formulary
Trial · NCT06466434
Prebiotic Food-enriched Diet (PreFED) to Enhance the Microbiome and Response to First-line Immunotherapy in Unresectable Melanoma
No UA site listed — international referral required
— невідомо— невідомо
self-pay: ₴0/course
Trial sponsor
Trial · NCT06428721
The Preventive Role of Fractionated Laser Resurfacing Against Actinic Neoplasia in an At-Risk Geriatric Population
No UA site listed — international referral required
— невідомо— невідомо
self-pay: ₴0/course
Trial sponsor
Trial · NCT04318717
Pembrolizumab and Hypofractionated Radiation Therapy for the Treatment of Mucosal Melanoma
No UA site listed — international referral required
— невідомо— невідомо
self-pay: ₴0/course
Trial sponsor
Trial · NCT06889766
NY-ESO-1-redirected T Cells in Patients With Advanced Melanoma and Sarcoma
No UA site listed — international referral required
— невідомо— невідомо
self-pay: ₴0/course
Trial sponsor
Trial · NCT04291105
Phase 2 Trial of Voyager V1 in Combination With Cemiplimab in Cancer Patients
No UA site listed — international referral required
— невідомо— невідомо
self-pay: ₴0/course
Trial sponsor
Trial · NCT07230613
Neo-adjuvant Immunotherapy in Patients With Localized Melanoma
No UA site listed — international referral required
— невідомо— невідомо
self-pay: ₴0/course
Trial sponsor
Trial · NCT07379138
Studying Quality of Life Inclusive of Mental Health and Cognitive Behavioral Therapy for Cancer Distress for the Improvement of Quality of Life in Stage III-IV Melanoma Patients
No UA site listed — international referral required
— невідомо— невідомо
self-pay: ₴0/course
Trial sponsor
Trial · NCT06028724
A Study on the Prevalence of Clinically Useful Mutations in Solid Tumor Characterized by Next Generation Sequencing Methods on Liquid Biopsy Analysis (POPCORN)
No UA site listed — international referral required
— невідомо— невідомо
self-pay: ₴0/course
Trial sponsor
Trial · NCT06797297
A Study to Evaluate the Efficacy and Safety of IBI363 Monotherapy Compared to Pembrolizumab in Patients With Unresectable Locally Advanced or Metastatic Mucosal or Acral Melanoma Who Had Not Previously Received Systemic Therapy
No UA site listed — international referral required
— невідомо— невідомо
self-pay: ₴0/course
Trial sponsor
Trial · NCT03740503
Genomic Investigation of Unusual Responders
No UA site listed — international referral required
— невідомо— невідомо
self-pay: ₴0/course
Trial sponsor

Інформація про ціни — orientation. Перевіряти у конкретній аптеці / foundation / трайл-сайті. Status updated: 2026-04-27.

plan_id: PLAN-AUTO-MELANOMA-001-V1 | version: 1 | generated: 2026-04-27T10:14:01.593853+00:00
Per FDA non-device CDS positioning (CHARTER §15): Outpatient oncology treatment planning to support tumor-board discussion. Not a medical device; not for autonomous clinical decision-making.
Per FDA non-device CDS positioning (CHARTER §15): Both treatment options below are presented for review. The engine's selection of a 'recommended' default does not constitute a clinical decision. Final treatment selection requires HCP judgment incorporating information not available to the system.
This document is an informational resource supporting tumor-board discussion (per CHARTER §11). It is not a system that makes clinical decisions. Every recommendation must be verified by the treating physician.